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Abstract—A new inhibitor, containing a linked proline-piperidine structure, for the enzyme prolyl oligopeptidase (POP) has been 
synthesised and demonstrated to bind covalently with the enzyme at the active site. This provides evidence that covalent inhibitors of POP 
do not have to be limited to structures containing 5-membered N-containing heterocyclic rings.  © 2010 Elsevier Science. All rights 
reserved 
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Introduction 
Prolyl Oligopeptidase
1
 (POP; also known as Prolyl 
Endopeptidase) was first discovered in 1979. The serine 
type endopeptidase is found in the active form in the 
cytosol, but does not digest polypeptides containing more 
than 30 amino acid residues. POP cleaves peptides at the 
carboxyl group of proline residues, and at a much slower 
rate at Ala residues
2a
 such specificity sharply contrasts with 
other serine proteases.  
 The POP crystal structure (Figure 1) was first 
determined by Fülop et al in 1998.
2a
 The enzyme consists 
of the catalytic and regulatory β-propeller domains. The 
catalytic domain has an α/β hydrolase fold. Both N- and C-
termini are exposed on the surface of the domain. The N-
terminus contains two anti-parallel β-sheets and two α-
helices that are linked with the non-catalytic domain. The 
C-terminal region of the catalytic domain is substantially 
larger and contains eight α-helices and an 8-stranded β-
sheets fragment. The active site is located at the interface 
with the central cavity. 
The disc-shaped 7-bladed β-propeller is mainly composed 
of anti-parallel β-strands and loops. Each blade contains 4 
twisted anti-parallel β-sheets. Typically, the ‗Molecular 
Velcro‘ is formed between the N- and C-termini of the 
domain, with the first strand located in the centre of the 
module. However, in POP the ―Velcro‖ is not closed.2b At 
first, it was postulated
2a
 that the first and the seventh blades 
may undergo conformational change to allow the diffusion 
of the substrate. Alternatively, the loops connecting both 
domains are situated within a close distance of each other 
and may act as a hinge.
3
 This theory was supported by the 
crystal structure of the open form of Sphingomonas  
capsulata POP.
4
 The two domains are held together in the 
closed form by salt bridges and other electrostatic 
interactions. The enzyme specificity for the unstructured 
oligopeptides containing up to 30 amino acid residues 
arises from the size of the internal cavity. Peptides 
possessing ordered secondary structure may not be 
accommodated at the active site. 
 
Figure 1: X-ray structure of Prolyl Oligopeptidase (POP). 
  The protein binds covalently to an inhibitor, Z-Pro-
Prolinal 1. The active site catalytic residues are depicted in 
Figure 2, which illustrates the binding of Ser554 to 1. The 
mechanism of the hemiacetal formation is identical to the 
first step of the generic peptide hydrolysis mechanism, and 
the reaction is reversible. However, the tetrahedral complex 
does not have a good leaving group (except serine) and 
therefore cannot be recycled. The inhibitor also forms 
hydrogen bonds with other residues in the oxyanion-
binding site and may not freely dissociate. 
    
Figure 2; Location of inhibitor 1 relative to the catalytic triad. 
 
 Prolyl Oligopeptidase is involved in the maturation and 
degradation of some neuropeptides and peptide hormones. 
The enzyme has been linked with the regulation of blood 
pressure, various central nervous system disorders, 
including Alzheimer‘s disease, schizophrenia and 
depression, and parasitic illnesses, such as Chagas disease 
(see SI for a summary Table). The development of new 
potent inhibitors is therefore highly desirable, and a large 
number of these have been reported, as summarized in a 
recent review.
1
 Known inhibitors which operate by a 
covalent mechanism (i.e. addition of serine OH to a 
functional group in the inhibitor) contain a five membered, 
heterocyclic ring, usually a pyrrolidine, structure. These 
N
O
N
O
O
H
O
1
 Bioorganic & Medicinal Chemistry  3
derivatives are close in structure to the natural substrates, 
which contain a proline group at the site adjacent to the 
position of amide cleavage. Furthermore, almost all non-
covalently binding inhibitors are also based on five 
membered heterocyclic ring structures at the position 
occupied by a proline in the natural substrates. 
 We wished to establish whether other small molecules, 
related in structure to Z-Pro-Prolinal 1, would also act as 
inhibitors. In particular, we selected compounds 2, with a 
piperidine rather than pyrrolidine ring, and 3, with an 
aromatic ring bearing the aldehyde (Figure 3). These 
compounds feature the same conserved Cbz-proline tail but 
would contain a different aldehyde module, hence offering 
the opportunity to retain some of the stabilising interactions 
present in 1. Inhibition of the enzyme by either 2 or 3 
would open a route to several further avenues for inhibitor 
development. Molecule 3 was of particular interest since, if 
it acted as an inhibitor, it would demonstrate for the first 
time that it is not essential to use 5-membered heterocyclic 
rings, in covalently-bond POP inhibitors.  
N O
N
O
O
CHO
N O
N
O
O
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2 3  
Figure 3: Potential inhibitors of POP. 
Results and Discussion. 
Our initial approach to 2 required conversion of carboxylic 
acid 4 to a protected aldehyde. Reduction of 4 was carried 
out with BH3 · DMS complex in THF to give 5 in high 
yield.
9
 Alcohol 5 was oxidised to an aldehyde using Swern 
conditions in 66% yield. Attempted protection of the 
aldehyde as an acetal failed to provide any protected 
product.
10,11
 At this point a different route was required. 
The alcohol of 5 was protected with a TBDMS group to 
give silyl ether 6.
12,13
 Imidazole was used in the reaction as 
a catalyst to activate TBDMS-Cl. A small volume of DMF 
was required to solubilise all the reaction components. 
4
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Scheme 1. Synthesis of inhibitor 2. 
 
Removal of the Boc protecting group was required before 
the peptide coupling step. Trifluoroacetic acid is commonly 
used to remove Boc groups.
14
 However, upon treatment of 
6 with TFA, only a complex mixture of products was 
obtained. Analytical data suggested that the TBDMS group 
had been affected during the reaction. Alternative methods 
for the removal of Boc protecting groups in the presence of 
acid labile moieties have been described.
15-19
 Following 
some investigations, zinc bromide (ZnBr2) in DCM in the 
presence of a catalytic amount of H2O provided amine 7 in 
80% yield. 
 The key step of the synthetic route was the formation of 
the peptide bond. The reaction was first attempted on amine 
7 using equimolar amounts of cbz-proline and slight excess 
of both DCC and DMAP
20,21
 in DCM under an argon 
atmosphere. This approach was partially successful, 
producing desired product 8, albeit in only 15% yield. 
EDCI.HCl and HOBt
22
 were also tried in the coupling 
reaction, but produced only trace amounts of the desired 
product. Ultimately, Cbz-proline was treated with thionyl 
chloride
23
 to produce the acid chloride which was then 
reacted with amine 7 in the presence of triethylamine in 
DCM to afford amide 8 in 50% yield. Compound 8 was 
then treated with TBAF in THF remove the TBDMS 
group,
24
 generating alcohol 9 in 64% yield. Swern 
oxidation of 9 then produced the desired aldehyde product 
2 in 68% yield. 
 The main building blocks of inhibitor 3 were Cbz-
proline and pyrrole-2-carboxaldehyde 10. To prevent any 
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possible side reactions, an attempt was made to protect the 
aldehyde group in 10 as an acetal.
10
 As before, this failed to 
provide any of the desired product. There are reports in the 
literature of pyrrole-2-carboxaldehyde 4 reactions forming 
porphyrin-related structures, and this is likely to have been 
the outcome here.
25
 An attempt was made to directly couple 
aldehyde 10 with Cbz-proline,
26
 but no product was 
observed.  Cbz-proline was therefore activated with thionyl 
chloride as before (Scheme 2) and a solution of pyrrole-2-
carboxaldehyde 10 and triethylamine in DCM was added.
27
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Scheme 2. Synthesis of (S)-benzyl 2-(2-formyl-1H-pyrrole-1-
carbonyl)pyrrolidine-1-carboxylate 3. 
 The desired product 3 was isolated from this reaction in 
a moderate yield (49%) after purification on silica, however 
it proved to be unstable on standing either at rt or -70
o
C, 
which hindered accurate binding studies with POP. 
Crystallisation studies. 
Porcine Prolyl Oligopeptidase (POP) was co-crystallized 
with inhibitor 2 using the hanging drop-vapour equilibrium 
method.
28
 Full details, and a typical diffraction image, are 
given in the Supporting Information. All data were indexed, 
integrated and scaled using the CCP4
29
 programs suite. The 
model was refined against the crystal structure of POP with 
Z-Pro-prolinal 1 inhibitor (1QFS.pdb) using Refmac.
30
 The 
data collection and processing statistics of a typical crystal 
are shown in Table 1. The crystal data information has been 
deposited with the RCSB Protein Data Bank (PDB) and 
assigned the code XXXX. 
Table 1. Data collection and processing statistics. Values in parentheses 
refer to the highest resolution shell (1.42-1.35 Å). 
  
 The model of the structure of the POP-2 complex is 
shown in Figure 4. β-Propeller and α/β hydrolase catalytic 
domains are well resolved and in agreement with the 
previously recorded structures. The β-propeller has 7 blades 
and the molecular ―Velcro‖ in not closed. The active site of 
the catalytic domain is buried in the cavity at the interface 
of the two domains. The inhibitor 2 molecule is in the 
centre cavity. Thre are no sufficiently large holes in the 
enzyme that would allow diffusion of the substrate 
peptides. Therefore Prolyl Oligopeptidase must undergo 
significant conformational changes to bind the substrate. 
 The cross-section of the model reveals more features of 
the active site (Figure 5); the key residues of the catalytic 
triad are shown as sticks. The Ser554 (cyan) is bound to 2, 
while His680 (green) and Asp641 (blue) are in close 
proximity. The solvent molecules are not displayed. The 
model (Figure 6) confirmed the structure of 2. The bond 
lengths of the hemiacetal group were restrained to their 
target values (C1-C2 = 1.55Å; C1-O1 = 1.43Å; C1-O-
Ser554 = 1.35Å). The hemiacetal group is in the axial 
position of piperidine ring to accommodate 2 in the active 
site. The conformation is also enforced by stacking with the 
aromatic Trp595 indole ring. Tryptophan is important for 
the specificity of POP for substrates with proline residues. 
The piperidine ring is similarly sized and fits well into the 
hydrophobic pocket. 
 
Figure 4. X-Ray crystal structure model of Prolyl Oligopeptidase with 
bound inhibitor 2 (pink). 
Synchrotron radiation 
Detector and wavelength (Å) 
Diamond 
ADSC CCD Q315, 
0.9702 
Space group P212121 
Unit cell parameters 
 a (Å) 
 b (Å) 
 c (Å) 
  = β =  (º) 
 
70.82 
99.51 
110.79 
90 
Molecules per AU 1 
Solvent convent by (%) 48 
Resolution range (Å) 51.20-1.35 
Total observations 796701 
Unique reflections 168680 
Rmerge (%)
a
 0.080 (0.648) 
Average I/σ(I)b 10.4 (2.1) 
Completeness (%) 98.5 (99.5) 
R-factor (%)c 16.4 
Rfree (%)
d 18.6 
aRmerge = ΣjΣh |Ih,j - <Ih>| / ΣjΣh<Ih> x 100, where Ih,j is the j
th 
observation of reflection h, and <Ih> is the mean intensity of that 
reflection. 
bI/σ(I), average of the diffraction intensities, divided by their standard 
deviations. 
cR-factor = Σhkl ||Fobs| - |Fcalc|| / Σhkl |Fobs|, where F are structure factors 
dRfree = Σhkl εT ||Fobs| - |Fcalc|| / Σhkl εT |Fobs|, where the test set (4% of the 
data) is omitted from the refinement in such a way that all structure 
factors in each of several thin resolution shells were selected 
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Figure 5. Cross-section of Prolyl Oligopeptidase crystal structure model 
showing the active site with the bound inhibitor 2 molecule (yellow); the 
surface of the protein is shown in light blue. Figures drawn with PyMol.31 
 His680 is in close proximity to Ser554 and involved in 
H-bonding interaction with Asp641.  The ―oxyanion hole‖ 
is formed with Tyr473 residue side chain and the main 
chain NH group of Asn555. Both groups form hydrogen-
bonds with O1 atom of 2. The binding of the substrate 2 is 
further stabilised with two hydrogen-bonds between O2 
and O3 with side chain NH groups of Arg643 and Trp595, 
respectively. Although the hemiacetal group is labile, the 
substrate remains bound in the active and can reform the 
covalent bond. 
 
Figure 6. Electron density map and the model of the active site residues of 
Prolyl Oligopeptidase with covalently bound (S)-benzyl 2-((S)-2-
formylpiperidine-1-carbonyl)pyrrolidine-1-carboxylate 2 (green). The 
SIGMAA weighted 2mFo - ΔFc electron density32 is contoured at the 1.5σ 
level, where σ represents the rms electron density for the unit cell. 
Contours more than 1.4 Å from any of the displayed atoms have been 
removed for clarity. Figure drawn with MolScript.33 
Inhibition Assays 
Z-Gly-L-Pro-4-nitroanilide 11 is a synthetic peptide that 
can be used for the kinetic activity assays of peptidases 
(Scheme 3). 4-Nitroaniline 12 is one of the products 
released from the enzymatic cleavage reaction. Compound 
12 strongly absorbs visible light at 410 nm, which allowed 
collecting the measurements with the UV/VIS 
spectrophotometer.  
N
ON
O
NHCO2CH2Ph
POP
H
NO2
11
OH
ON
O
NHCO2CH2Ph
H2N NO2
12
+
 
 
Scheme 3. Cbz-Gly-L-Pro-4-nitroanilide 11 is cleaved by Prolyl 
Oligopeptidase. 4-nitroaniline 12 is released in to solution and absorbs 
strongly at 410 nm (appears yellow). 
The optimum concentration of 11 was determined by the 
kinetic digestion assays (see Supporting Information). The 
saturation of POP (176 µg/ml) was reached at around 90 
µM concentration of the synthetic peptide 12. KM = 27 µM 
was the concentration of the substrate 12 at which the 
reaction proceeded at the half-maximal velocity. The IC50 
of 3 could not be precisely determined because it had 
degraded over 3 weeks (50% purity was determined by 
1
H 
NMR). The preliminary measurements indicated the IC50 
value could be in a range of 10-100 µM. The low activity 
could be associated with the conjugation of the aldehyde 
group with the aromatic pyrrole ring. The assays also 
suggested that the activity of POP was adversely affected 
by DMSO. However, DMSO was necessary to dissolve 
organic compounds including 2, 3 and 11. 
 Inhibitor 2 was stable and kinetic measurement data 
could be collected. The Prolyl Oligopeptidase (176 µg/ml) 
activity was measured with Z-Gly-Pro-4-nitroanilide 11 as 
the substrate. IC50 values were measured by following the 
residual activity of the enzyme using 100 µM substrate 11 
with various concentrations of compound 2 (Figure 7). 
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Figure 7. Kinetic measurements of the inhibition of Prolyl Oligopeptidase 
with 2. 
Compound 2 was a very potent inhibitor (IC50 ≈ 26 nM); 
however its activity was slightly lower when compared 
with Z-Pro-prolinal 1. Ki = IC50/(1 + [11]/Km) = 4.3 nM . 
Conclusions. 
In conclusion, two potential POP inhibitors, 2 and 3, have 
been synthesised, isolated and characterised.  Compound 2 
was co-crystallised with Prolyl Oligopeptidase using the 
hanging drop-vapour equilibrium method. The X-ray 
crystal structure was successfully determined at 1.35Å 
maximum resolution. The crystal structure model revealed 
that inhibitor 2 covalently bound to the Ser554 residue in 
the active site. This provides direct evidence that POP 
inhibitor structures need not be limited to five-membered 
N-containing rings at the position where covalent 
attachment to an the enzyme takes place. The enzyme 
inhibition assays revealed that 2 is a potent inhibitor (IC50 = 
26 nM). This confirms that piperidine ring-containing 
compounds also act as effective substrate mimics for the 
POP enzyme, thus opening up new possibilites for the 
development of new synthetic inhibitors for POP based on 
alternative ring structures. Compound 3 degraded before it 
could be co-crystallised with POP. Preliminary kinetics 
measurements however indicated a low inhibitory potential 
of 3. 
Experimental 
All reactions were carried out under ambient conditions 
unless otherwise stated in the method. Anhydrous grade 
solvents were supplied commercially in sealed bottles, 
while DMSO and triethylamine were distilled. Unless 
otherwise stated, reactions were monitored by NMR and 
thin layer chromatography using aluminum-backed silica 
gel 60 (F254) plates, visualizing with a KMnO4 stain. 60 Å 
silica gel (Merck) was used for flash column 
chromatography. NMR spectra were recorded on a Bruker 
DPX-400 (
1
H 400 MHz, 
13
C 100 MHz) and Bruker AVII-
700 (
1
H 700 MHz, 
13
C 176 MHz) spectrometers unless 
otherwise specified. Chemical shifts are reported in ppm on 
the δ scale standardized against TMS, where δTMS = 0 ppm. 
Coupling constants are measured in Hz. IR spectra were 
recorded on a Perkin-Elmer Spectrum One FT-IR 
spectrometer. Low resolution mass spectra were recorded 
on a Bruker Esquire 2000 mass spectrometer. HR-MS were 
recorded on Bruker MicroTOF mass spectrometer. Melting 
points were recorded on a Stuart Scientific SMP 1 
instrument and optical rotations on a Perkin-Elmer 241 
polarimeter. The kinetics data was recorded with Varian 
Cary 100 Bio UV/Vis spectrophotometer. The X-ray 
crystallographic data was acquired on the beamline IO4 at 
the DIAMOND synchrotron using an ADSC CCD Q315 
detector. 
(S)-tert-Butyl 2-(hydroxymethyl)piperidine-1-carboxylate 5. 
A solution of (S)-(-)-N-Boc-carbonyl-2-piperidinine 
carboxylic acid 4 (2.3 g, 10 mmol, 1.0 equiv) in THF (15 
mL) was stirred under a nitrogen atmosphere and cooled to 
0 C, at which point 2M BH3 DMS in THF (10 mL, 10 
mmol, 2.0 equiv) was carefully added over 5 minutes. The 
reaction mixture was kept at this temperature for additional 
5 h, and then left to warm up overnight. The reaction was 
confirmed to be complete by TLC analysis. Water (40 mL) 
was slowly added to quench the reaction. Ethyl acetate (220 
mL) was added and the mixture was separated. The organic 
layer was washed with saturated aqueous solutions of NaCl 
(40 mL), NaHCO3 (40 mL), distilled water (2x 40 mL) and 
finally brine (40 mL). The organic phase was dried over 
MgSO4 and was concentrated in vacuo to yield crude 
alcohol 5 (1.92 g, 8.9 mmol, 89%).  Product 5 was used in 
the next step without purification. White solid (1.917 g, 
8.91 mmol, 89%); Mp 80-81 °C; [ ]D
23
 -39.3 (c 2.0 in 
CHCl3) (S), (lit.
34 [α]D
20
 -31.2 (c 2.00 in CHCl3) (S)); 
(Found: C, 61.14; H, 9.73; N, 6.51. C11H21NO3 requires C, 
61.37; H, 9.83; N, 6.51%); (Found: (ESI+) 238.1410 (M + 
Na
+
). C11H21NNaO3 requires 238.1414); νmax 3708 (amide 
N-H str), 3441 (O-H str), 2940 (C-H str), 2868, 1652 (C=O 
str), 1414, 1365, 1278,  1048, 871, and 772 cm
−1
; δH (400 
MHz; CDCl3; Me4Si) 4.30 (1 H, m, N-CH), 3.94 (1 H, br d, 
J 12.8, N-HCH), 3.82 (1 H, br d, J 10.0, –HCH-O), 3.61 (1 
H, dd, J 5.8, 10.9, -HCH-O), 2.87 (1 H, br dd, J 11.5, N-
HCH), 2.17 (1 H, br s, -OH), 1.72-1.35 (6 H, m, -(CH2)3-) 
and 1.46 (9 H, s, -C(CH3)3); δC (100 MHz; CDCl3; Me4Si) 
79.86 (OCMe3), 61.81 (-CH2-OH), 52.57 (N-CH), 40.06 
(N-CH2), 28.47 (3x CH3), 25.31 (CH2), 25.26 (CH2) and 
19.68 (CH2); m/z (ESI+) 238 (M+Na
+
, 100%), 182 (M
+
-
t
Bu 
+ Na
+
, 15) and 116 (M
+
-BOC, 7). Data is consistent with 
that reported in the literature
34,35 
(S)-tert-Butyl 2-formylpiperidine-1-carboxylate. To a 
stirred 2 M solution of oxalyl chloride (10.15 mL, 20.3 
mmol, 2.9 equiv) in anhydrous DCM at -78°C was added 
dropwise a solution of anhydrous DMSO (2.55 mL, 35 
mmol, 5.0 equiv) in anhydrous DCM (7.5 mL). After 5 min 
a solution of (S)-tert-butyl 2-(hydroxymethyl)piperidine-1-
carboxylate 5 (1.5 g, 7 mmol, 1.0 equiv) in anhydrous 
DCM (7.5 mL) was added dropwise. Triethylamine (8.5 
mL, 61 mmol, 8.7 equiv) was added 30 min later. The 
colourless reaction mixture instantly became yellow. The 
reaction was allowed to warm up to room temperature. The 
mixture was then poured into distilled water (40 mL), and 
the organic layer was separated. The aqueous layer was 
extracted with dichloromethane (4x 25 mL). The organic 
fractions were combined and washed with brine (25 mL), 
saturated NaHCO3 aqueous solution (25 mL), and distilled 
water (25 mL). The organic layer was dried over 
magnesium sulphate and concentrated in vacuo to give the 
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product as a brown oily residue(1.40 g 93% crude). The 
crude oil was purified on silica using hexane : ethyl acetate 
(50 : 50) eluent system (Rf = 0.233 with 10 : 90 hexane : 
ethyl acetate). The compound was isolated as a yellow oil 
(0.984 mg, 4.61 mmol, 66%, pure). A small amount of 
starting material 5 was recovered.; [ ]D
23
 -37.7 (c 1.48 in 
CHCl3) (S), (lit.
36 [α]D
20
 -77.9 (c 1.49 in CHCl3) (S)); 
(Found: (ESI+) 236.1259 (M + Na
+
). C11H19NNaO3 
requires 236.1257); νmax 2975, 2940 (C-H str), 2861, 1733, 
1686 (C=O str), 1447, 1392, 1365, 1275, 1249, 1160, 1044, 
870, and 770 cm
−1
; δH (400 MHz; CDCl3; Me4Si, rotamers) 
9.59 (1 H, s, -COH), 4.56 (1 H, m, N-CH), 3.95 (1 H, m, 
N-HCH), 2.92 (1 H, m, N-HCH), 2.16 (1 H, m, N-CH-
HCH), 1.50-1.73 (4 H, m, alkyl-H), 1.47 (9 H, s, -C(CH3)3) 
and 1.15-1.35 (1 H, m, alkyl-H); δC (100 MHz; CDCl3; 
Me4Si, rotamers) 201.34 (COH), 80.42 (OCMe3), 60.76, 
28.26 (3x CH3), 24.73 (CH2), 23.64 (CH2) and 20.96 (CH2); 
m/z (ESI+) 236 (M+Na
+
, 100%), 180 ([M+Na]
+
-
t
Bu, 48) 
and 114 (M
+
-BOC, 69). Data is consistent with that 
reported in the literature
35,37 
(S)-tert-Butyl-2-((tert-butyldimethylsilyloxy)methyl-
)piperidine-1-carboxylate 6. (S)-tert-Butyl 2-
(hydroxymethyl)piperidine-1-carboxylate 5 (1.00 g, 4.64 
mmol, 1.0 equiv) was treated with imidazole (0.95 g, 13.9 
mmol, 3.0 equiv) and TBDMS-Cl (1.04 g, 6.96 mmol, 1.5 
equiv) in a mixture of DCM (60 mL) and dry DMF (17 
mL) at room temperature. After 36 hours the reaction was 
confirmed complete by TLC analysis. Diethyl ether (90 
mL) was added, and the precipitate was filtered off. The 
filtrate was concentrated in vacuo to a crude oily residue 6. 
The product was purified on silica using gradient hexane : 
ethyl acetate eluent system to give 6 (1.48 g, 4.48 mmol, 
97%) as a colourless oil; [ ]D
23
 -35.8 (c 0.60 in CHCl3) (S), 
(lit.
38 [α]D
20
 +34.9 (c 0.59 in CHCl3) (R)); (Found: (ESI+) 
352.2276 (M + Na
+
). C17H35NNaO3Si requires 352.2278)); 
νmax 2930, 2857, 1692, 1408, 1364, 1251, 1140, 1090, 834, 
774 cm
−1
; δH (400 MHz; CDCl3; Me4Si) 4.17 (1 H, br, -N-
CH-), 3.98 (1 H, br d, J 11.5, -N-HCH-), 3.68 (1 H, dd, J 
9.2, -HCH-O-), 3.58 (1 H, dd, J 6.0, 9.7, -HCH-O-), 2.73 
(1 H, br dd, J 12.6, -N-HCH-), 1.85 (1 H, br d, J 7.5), 1.69-
1.25 (5 H, m, alkyl-H), 1.45 (9 H, s, BOC -CH3), 0.88 (9 
H, s, TBDMS -(CH3)3) and 0.05 (6 H, s, 2x -Si-CH3); δC 
(100 MHz; CDCl3; Me4Si) 155.23 (-C=O), 79.18 (-O-
CMe3), 60.85 (-CH2-O-), 51.84 (-N-CH-), 51.73, 40.27 (-
N-CH2-), 40.01, 28.53 (BOC -CH3), 25.94 (TBDMS -
(CH3)3), 25.36 (CH2), 24.49 (CH2), 19.16 (CH2), 18.28 (-
Si-CMe3), -5.30 (-Si-CH3) and -5.36 (-Si-CH3); m/z (ESI+) 
352 (M+Na
+
, 100%). 
(S)-2-((tert-Butyldimethylsilyloxy)methyl)piperidine 7. To a 
dry round bottomed flask were charged (S)-tert-butyl 2-
((tert-butyldimethylsilyloxy)methyl)piperidine-1-
carboxylate 6 (600 mg, 1.82 mmol, 1.0 equiv), zinc 
bromide (2.06 g, 9.12 mmol, 5.0 equiv) and DCM (13 mL). 
The reaction was stirred at ambient conditions overnight.  
The reaction mixture was diluted with diethyl ether (150 
mL) and sat. NaHCO3 aq. sol. (150 mL) was added. The 
organic phase was separated, and the aqueous layer was 
extracted with further diethyl ether portions (3x 100 mL). 
The combined organic phases were dried over MgSO4 and 
concentrated under reduced pressure to give 7 (333 mg, 
1.45 mmol, 80%) as a colourless oil. The material 7 was 
used in the next step without purification. Colourless oil 
(333 mg, 1.45 mmol, 80%); [ ]D
22
 +3.59 (c 1.48 in CHCl3) 
(S); (Found: (ESI+) 230.1940 (M + H
+
). C12H28NOSi 
requires 230.1935)); νmax 2978, 2857, 1472, 1463, 1446, 
1330, 1253, 1087, 1075, 832, 774 cm
−1
; δH (400 MHz; 
CDCl3; Me4Si) 3.52 (1 H, dd, J 3.8, 9.6, -O-HCH-), 3.38 (1 
H, dd, J 8.9, 8.9, -O-HCH-), 3.06 (1 H, br d, J 11.5, -N-
HCH-), 2.61 (1 H, ddd, J 2.6, 11.5, 11.6, -N-HCH-), 2.54-
2.62 (1 H, m, -N-CH-), 2.13 (1 H, br s, NH), 1.77 (1 H, br 
d, J 12.5, -N(CH2)2-HCH-), 1.58 (1 H, br d, J 12.8, -NCH2-
HCH-), 1.49 (1 H, m, -NCH-HCH-), 1.23-1.46 (2 H, m), 
1.06 (1 H, dddd, J 3.8, 12.3, 12.3, 12.3, -NCH-HCH-), 0.88 
(9 H, s, TBDMS (CH3)3) and 0.03 (6 H, s, 2x -Si-CH3); δC 
(100 MHz; CDCl3; Me4Si) 67.93 (-CH2-O-), 58.32 (-N-CH-
), 46.67 (-N-CH2-), 28.47 (-NCH-CH2-), 26.47 (-NCH2-
CH2-), 25.95 (TBDMS (-CH3)3), 24.46 (-N(CH2)2-CH2-), 
18.32 (-Si-CMe3), -5.37 (-Si-CH3); m/z (ESI+) 230 (M+H
+
, 
100%). 
(S)-Benzyl-2-((S)-2-((tert-butyldimethylsilyloxy)methyl)-
piperidine-1-carbonyl)pyrrolidine-1-carboxylate 8. 
Coupling method A. To a dry, clean round bottomed flask 
were added cbz-proline (166 mg, 0.668 mmol, 1.0 equiv), 
HOBt (115 mg, 0.741 mmol, 1.11 equiv), EDCI HCl (157 
mg, 0.800 mmol, 1.0 equiv), DMF (0.06 mL) and DCM 
(1.5 mL). The mixture was degassed, purged with argon, 
and stirred for 10 min. (S)-2-((tert-
butyldimethylsilyloxy)methyl)piperidine 7 was dissolved in 
DCM (6 mL) and was added to the reaction. The reaction 
mixture was degassed, purged with argon and stirred at 
ambient conditions. The progress was monitored by ESI+ 
MS, and TLC.  After 3 days, the desired product 10 was 
detected in the mixture, however the major component was 
still the starting amine 7. Triethylamine (0.07 mL) was 
added. A day later the reaction composition was 
unchanged; another 0.5 equiv of HOBt, and EDCI, and 1 
mL of triethylamine were charged. A day later NMM (1 
mL) was added. After 4 days the reaction did not progress 
any further. The material was combined with another 
reaction mixture (NMM was used instead of DMF, no 
Et3N, and 1.2 equiv of EDCI), poured into water and 
extracted with DCM. The organic layer was washed twice 
with citric acid aq. solution, twice with NaHCO3 aqueous 
solution, brine, and dried over MgSO4. The organic phase 
was concentrated in vacuo to yellowish oil (0.247 g), which 
was purified on silica using gradient hexane : ethyl acetate 
eluent system to give 8 (0.128 g, 0.277 mmol, 28%) as a 
clear colourless oil; [ ]D
25
 -30.45 (c 0.56 in CHCl3) (SS); 
(Found: (ESI+) 483.2636 (M + Na
+
). C25H40N2NaO4Si 
requires 483.2650); νmax 2928, 2855 (C-H str), 1704, 1649 
(C=O str), 1498, 1412, 1350, 1248, 1210, 1171, 1103, 
1024, 872, 775 and 696 cm
−1
; δH (700 MHz; CDCl3; Me4Si, 
rotamers) 7.25-7.40 (5 H, m, Ph-CH), 4.91-5.25 (2 H, m, -
C(=O)OCH2-),  4.49-4.80 (2 H, m, Pro–N-CH-, Pip—N-
CH- (1 conformer), -N-HCH- (1 conformer)), 3.49-3.93 (4 
H, m, -CH2-OSi- (1½ H), Pip—N-CH- (1 conformer), -N-
CH2- (1½ H), -N-HCH- (1 conformer)), 3.04-3.22 (1 H, m, 
-N-HCH- (1 conformer), -CH2-OSi- (½ H)), 2.61 (½ H, 
ddd, J 13.4, 13.4, 2.7, -N-HCH- (1 conformer)), 2.43 (½ H, 
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ddd, J 13.4, 13.4, 2.7, -N-HCH- (1 conformer)), 1.12-2.30 
(10 H, m, alkyl-H), 0.91, 0.89, 0.88 and 0.83 (9 H, 4x s, 
TBDMS (CH3)3) and -0.09-0.10 (6 H, m, 2x -Si-CH3); δC 
(176 MHz; CDCl3; Me4Si, rotamers) 171.08, 171.06, 
170.72 and 170.63 (-NC(=O)CH-), 154.88, 154.77, 154.41 
and 154.37 (-NC(=O)O-), 136.97, 136.81 and 136.73 (Ph-
C1), 128.46, 128.37, 128.27, 128.25, 128.15, 127.92, 
127.87, 127.76 and 127.35 (Ph-C2,3,4,5,6), 67.06, 66.95, 
66.77 and 66.73 (-C(=O)OCH2-), 61.51, 61.35, 60.27 and 
59.83 (-SiO-CH2-), 57.48, 57.33, 57.13 and 56.86 (-NCH-), 
53.64, 53.50, 49.64 and 49.60 (-NCH-), 47.20, 47.10, 46.57 
and 46.56 (-NCH2-), 42.16 and 41.78, 38.44 and 38.35 (-
NCH2-), 30.94, 30.45, 30.07 and 29.49 (-CH2-), 25.91, 
25.87, 25.84 and 25.80 (TBDMS (-CH3)3), 25.58, 25.40, 
25.13 and 25.04 (-CH2-),  24.67, 24.63, 24.52 and 24.46 (-
CH2-),  24.11, 24.00, 23.35 and 23.25 (-CH2-), 19.49, 
19.42, 18.89 and 18.73 (-CH2-), 18.23, 18.20 and 18.12 (-
Si-CMe3), -5.23, -5.42, -5.47 and -5.57 (-Si-CH3); m/z 
(ESI+) 483 (M+Na
+
, 48%), 461 (M+H
+
, 100) and 329 (M
+
-
OTBDMS, 6). 
(S)-Benzyl-2-((S)-2-((tert-butyldimethylsilyloxy)methyl)-
piperidine-1-carbonyl)pyrrolidine-1-carboxylate 8. 
Coupling method B. To a dry, clean round-bottomed flask 
were added cbz-proline (196 mg, 0.758 mmol, 1.0 equiv), 
dry toluene (3 mL), and thionyl chloride (0.10 mL, 1.36 
mmol, 1.8 equiv). The reaction mixture was degassed and 
purged with argon two times. The reaction was stirred 
under reflux conditions under nitrogen atmosphere for 1.5 
h. [A colour change was noted shortly after heating began 
when the mixture became yellow]. The reaction was 
allowed to cool down to room temperature, and the reaction 
mixture was concentrated to dark yellow oil in vacuo. In a 
separate flask a solution of (S)-2-((tert-
butyldimethylsilyloxy)-methyl)piperidine 7 (178 mg, 0.78 
mmol, 1.0 equiv), and triethylamine (0.33 mL, 2.36 mmol, 
3.0 equiv) was prepared in DCM (2 mL). The mixture was 
carefully added to the acyl chloride. The resulting mixture 
was degassed and purged with argon. The reaction was 
stirred for 1 d under argon atmosphere. The mixture was 
poured into 0.1 M HCl aq. (30 mL). DCM (20 mL) was 
added and phases were separated. The aqueous layer was 
extracted with another portion of DCM (20 mL). The 
organic fractions were combined and washed successively 
with distilled water (20 mL), brine (25 mL), sat. Na2CO3 
aq. sol. (2x 30 mL), brine (25 mL), and dried over MgSO4. 
The organic layer was concentrated in vacuo to crude oil 8 
(213 mg). The oil was separated on silica using hexane : 
ethyl acetate (100 : 0 to 60 : 40) gradient eluent system. 
The desired product was isolated as colourless oil 8 (175 
mg, 0.38 mmol, 50%); [ ]D
25
 -25.38 (c 0.47 in CHCl3) 
(SS); matching NMR data described in previous section. 
(S)-Benzyl-2-((S)-2-(hydroxymethyl)piperidine-1-
carbonyl)pyrrolidine-1-carboxylate 9. (S)-Benzyl 2-((S)-2-
((tert-butyldimethylsilyloxy)methyl)piperidine-1-
carbonyl)-pyrrolidine-1-carboxylate 8 (92 mg, 0.2 mmol, 
1.0 equiv) was dissolved in THF (1.2 mL), and cooled in an 
ice bath. 1 M TBAF solution in THF (0.40 mL, 0.40 mmol, 
2.0 equiv) was carefully added, while the reaction was 
stirred at +4 C. After 2 h distilled the reaction was 
complete and water was added to quench the reaction. The 
suspension was extracted with DCM, and diethyl ether. The 
organic layer was washed with brine, dried over MgSO4 
and was concentrated in vacuo (64 mg). The material 9 was 
purified on silica using hexane : ethyl acetate eluent system 
to give the desired product 9 (44 mg, 0.127 mmol, 64%); 
[ ]D
28
 -34.0 (c 0.97 in CHCl3) (SS); (Found: (ESI+) 
347.1964 (M + Na
+
) and 369.1795 (M + H
+
). C19H27N2O4 
requires 347.1965; C19H27N2NaO4 requires 369.1785); νmax 
3413 (O-H str), 2939, 2873 (C-H str), 1697, 1631 (C=O 
str), 1415, 1352, 1254, 1209, 1167, 1120, 1021, 919, 728 
and 697 cm
−1
; δH (700 MHz; CDCl3; Me4Si, rotamers) 
7.19-7.32 (5 H, m, Ph-CH), 4.91-5.20 (2 H, m, -
C(=O)OCH2-), 4.45-4.91 (2 H, m, -N-CH- (½ H), -N-
HCH- (½ H)), 4.13 (½ H, br s, -N-CH- (1 conformer)), 
4.06 (½ H, dd, J 4.1, 9.9, -HCH-OH (1 conformer)), 3.41-
3.86 (3½ H, m, -HCH-OH (1½ H), -N-HCH- (2 H)), 3.24 
(¼ H, m, -N-HCH- (1 conformer)), 3.07 (¼ H, ddd, J 2.5, 
12.9, -N-HCH- (1 conformer)), 3.00 (¼ H, ddd, J 2.5, 12.9, 
-N-HCH- (1 conformer)), 2.69 (½ H, dt, J 2.6, 13.4, -N-
HCH- (1 conformer)), 2.50 (1 H, br s, -OH), 2.40 ((¼ H, 
dt, J 2.6, 13.4, -N-HCH- (1 conformer)) and 1.10-2.25 (10 
H, m, alkyl-H); δC (176 MHz; CDCl3; Me4Si, rotamers) 
173.15, 173.04, 172.15 and 171.81 (-NC(=O)CH-), 155.41, 
154.97, 154.41 and 154.36 (-NC(=O)O-), 136.94, 136.80, 
136.68 and 136.60 (Ph-C1), 128.67, 128.57, 128.50, 
128.39, 128.35, 127.99, 127.93, 127.88 and 127.83 (Ph-
C2,3,4,5,6), 67.34, 67.25, 67.06 and 66.94 (-C(=O)OCH2-), 
62.33, 62.21, 62.02 and 60.84 (HO-CH2-), 57.84, 57.30, 
57.20 and 56.79 (-NCH-), 55.53, 54.34, 51.18 and 51.08 (-
NCH-), 47.30, 47.26, 46.99 and 46.75 (-NCH2-), 41.56, 
41.25 and 37.14 (-NCH2-), 30.72, 30.50, 29.98 and 29.50 (-
CH2-), 27.68, 26.46, 25.45, 25.32, 25.25, 24.95, 24.83, 
24.71, 24.12, 23.52, 23.40, 24.11, 24.00, 23.52 and 23.40 
(3x -CH2-) and 19.94, 19.72, 19.68 and 19.56 (-CH2-); m/z 
(ESI+) 385 (M+K
+
, 3%), 369 (M+Na
+
, 100), 347 (M+H
+
, 
72) 329 (M
+
-OH, 21), 303 (M
+
-43, 48) and 239 (M
+
-
PhCH2O, 3). 
(S)-Benzyl-2-((S)-2-formylpiperidine-1-
carbonyl)pyrrolidine-1-carboxylate 2. To a stirred 2 M 
solution of oxalyl chloride (184.5 μl, 0.369 mmol) in 
anhydrous DCM at  
-78 °C was added dropwise solution anhydrous DMSO (50 
μL, 0.637 mmol) in anhydrous DCM (0.10 mL). After 10 
min solution of (S)-benzyl 2-((S)-2-
(hydroxymethyl)piperidine-1-carbonyl)pyrrolidine-1-
carboxylate 9 (44 mg, 0.127 mmol) in anhydrous DCM 
(0.15 mL) was added dropwise. After 3 h a low resolution 
MS sample was taken; m/z+1=347. Triethylamine (0.154 
mL, 1.11 mmol) was added. The colourless reaction 
mixture instantly became yellow. The reaction was allowed 
to warm up to room temperature. The mixture was then 
poured into distilled water (5 mL), and was separated. The 
aqueous layer was extracted with dichloromethane (3 x 10 
mL). The organic fractions were combined and washed 
with brine, saturated NaHCO3 aqueous solution, distilled 
water, and brine. The organic layer was dried over 
magnesium sulphate and concentrated in vacuo to give 
yellow oily residue 2 (60 mg, crude). Low resolution MS 
analysis confirmed it as the desired product 2; m/z+1=301, 
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345, 367. 
1
H NMR also confirmed the formation of the 
product 2. The crude oil 2 was purified on silica using 
gradient hexane : ethyl acetate eluent system (Rf = 0.145 
with 50 : 50 hexane : ethyl acetate). The compound was 
isolated as a colourless oil 2 (29.7 mg, 0.086 mmol, 68%); 
[ ]D
23
 -45.2 (c 1.0 in CHCl3) (SS), (Found: (ESI+) 
367.1630 (M + Na
+
). C19H24N2NaO4 requires 367.1628); 
νmax 2943 (C-H str), 2873, 1699, 1648 (C=O str), 1412, 
1351, 1237, 1165, 1117, 764, 742, and 697 cm
−1
; δH (700 
MHz; CDCl3; Me4Si, rotamers) 9.52 and 9.47 (1 H, 2x s, -
COH), 7.20-7.45 (5 H, m, Ph-CH), 4.91-5.23 (3 H, m, -
C(=O)OCH2, -N-CH-), 4.82 (½ H, dd, J 2.8, 8.7, -N-CH- 
(1 conformer)), 4.73 (½ H, dd, J 2.8, 8.7, -N-CH- (1 
conformer)), 3.85 (½ H, d, J 13.3, -N-HCH- (1 
conformer)), 3.62-3.73 (1½ H, m, -N-HCH- (1½ H)), 3.48-
3.62 (1 H, m, -N-HCH-), 3.13 (½ H, dd, J 2.9, 12.7, -N-
HCH- (1 conformer)), 3.04 (½ H, dd, J 2.9, 12.7, -N-HCH- 
(1 conformer)) and 1.11-2.29 (10 H, m, alkyl-H); δC (176 
MHz; CDCl3; Me4Si, rotamers) 202.18, 201.33, 201.08 and 
200.14 (-COH), 172.45, 172.35 and 171.94 (-NC(=O)CH-), 
155.04, 154.99, 154.90 and 154.33 (-NC(=O)O-), 136.95 
and 136.82 (Ph-C1), 128.52, 128.43, 128.06, 128.01, 
127.95 and 127.82 (Ph-C2,3,4,5,6), 67.12 and 66.97 (-
C(=O)OCH2-), 59.43 and 59.20 (-NCH-), 57.41 and 56.77 
(-NCH-), 47.25 and 46.72 (-NCH2-), 44.00 and 43.80 (-
NCH2-), 30.59 and 29.50 (-CH2-), 25.08, 25.03, 24.45, 
24.11, 23.41 and 23.14 (3x -CH2-) and 21.19 and 21.13 (-
CH2-); m/z (ESI+) 367.1 (M+Na
+
, 34%), 345.2 (M+H
+
, 
100) and 301.2 (M
+
-CH2COH, 16). 
(S)-Benzyl 2-(2-formyl-1H-pyrrole-1-carbonyl)pyrrolidine-
1-carboxylate 3. To a dry, clean round bottomed flask were 
added cbz-proline (1.05 g, 4.2 mmol, 1.0 equiv), dry 
toluene (10 mL), and thionyl chloride (0.55 mL, 7.56 
mmol, 1.8 equiv). The reaction mixture was degassed and 
purged with argon two times. The reaction was stirred 
under reflux conditions under nitrogen atmosphere for 1.5 
h. [A colour change was noted shortly after heating began 
when the mixture became yellow]. The reaction was 
allowed to cool down to room temperature, and the reaction 
mixture was concentrated to a dark yellow oil in vacuo. In a 
separate flask a solution of pyrrole-2-carboxaldehyde 10 
(600 mg, 6.3 mmol, 1.5 equiv), and triethylamine (0.62 mL, 
8.4 mmol, 2.0 equiv) were mixed in DCM (10 mL). The 
mixture was carefully added to the acyl chloride prepared 
in the previous step. The resulting mixture was degassed 
and purged with argon. The reaction was stirred for 1 d 
under nitrogen atmosphere. The mixture was poured into 
0.1 M HCl aq. (21 mL). DCM (40 mL) was added and 
phases were separated. The organic fraction was washed 
successively with distilled water (20 mL), brine (50 mL), 
sat. Na2CO3 aq. Sol. (150 mL), distilled water (2x 100 mL), 
brine (100 mL), and dried over MgSO4. The organic layer 
was concentrated in vacuo to crude dark green oil 3 (1.02 
g). The oil was separated on silica using hexane : ethyl 
acetate (100 : 0 to 50 : 50) gradient eluent system. The 
desired product 3 (670 mg, 2.05 mmol, 49%) was isolated 
as colourless oil, which darkened and degraded over time; 
[ ]D
20
 -101.28 (c 1.26 in CHCl3) (S); (Found: (ESI+) 
349.1165 (M + Na
+
). C18H18N2NaO4 requires 349.1159); 
νmax 3124, 2957, 2885 (C-H str), 1695, 1663 (C=O str), 
1547, 1443, 1410, 1353, 1259, 1170, 1110, 1023, 978, 871, 
773 and 695 cm
−1
; δH (400 MHz; CDCl3; Me4Si, rotamers) 
10.30 and 10.11 (1 H, s, -COH), 7.51 and 7.33 (1 H, br d, J 
1.57, -NCH=CH-), 7.10-7.45 (5 H, m, Ph-CH), 7.20-7.30 
(1 H, m, -NC=CH-), 6.42 and 6.34 (1 H, dd, J 3.3, 
NCH=CH), 4.98-5.25 (3 H, m, -OCH2- and -NCH-CH=O), 
3.57-3.85 (2 H, m, -NCH2-), 2.45 (1 H, m, -NCHCH2-), 
1.95-2.23 (3 H, m, -NCHCH2- and -NCH2CH2-); δC (100 
MHz; CDCl3; Me4Si, rotamers) 182.30 and 181.94 (-COH), 
171.81 and 171.57 (-NC(=O)CH-), 155.86 and 155.07 (-
NC(=O)O-), 136.38, 135.93 and 135.72 (C-COH and Ph-
C1), 128.53 and 128.45, 128.13, 127.90 and 127.85 (Ph-
C2,3,4,5,6), 125.86 and 125.56 (-NCH=CH-), 123.28 and 
122.98 (-NC=CH-), 113.27 and 113.22 (-NCH=CH-), 
67.41 (-OCH2-), 59.98 and 59.46 (-NCH-CH=O), 47.19 
and 46.68 (-NCH2-), 31.64 and 30.61 (-NCHCH2-), 24.44 
and 23.60 (-NCH2CH2-); m/z (ESI+) 349 (M+Na
+
, 70%), 
327 (M+H
+
, 100), 309 (M
+
-17, 3), 283 (17) and 255 (10). 
Compound 3 degraded on standing, and could not be 
recovered by column chromatography. The sample was 
stored in a flask filled with argon under -70 C; however 
the colourless oil quickly degraded. The compound visually 
darkened and eventually formed a black gum. The change 
of the 
1
H NMR spectrum of 3 after 3 weeks from isolation 
is shown in the Supporting Information. Compound 3 was 
unstable which hindered accurate studies of 3 with the POP 
enzyme. 
Crystallisation studies. Crystals were grown using the 
hanging drop-vapour equilibrium method.
28
 The 
composition of mother liquor in the reservoir was varied 
around 18-20% methoxy-polyethylene glycol (mPEG) 5K, 
20 mM Ca(OAc)2, 0.1 M TRIS pH=8.5 and 15% glycerol. 
Prolyl Oligopeptidase 8.8 mg/ml solution in 20 mM MES 
pH=6.5 was mixed with the precipitation buffer in a 2:1 
ratio. The 3 µL drops of the mixture were suspended over 
the wells and left to equilibrate. Small crystals were formed 
and used as seeds. Prolyl Oligopeptidase 8.8 mg/ml 
solution and inhibitor 2 4.4 mM solution in DMSO were 
mixed in a 10:1 ratio. The enzyme-inhibitor mixture was 
further diluted with the corresponding buffer solution in a 
2:1 ratio. The 3 µL drops were allowed to pre-equilibrate 
with the reservoir solution and were seeded with the micro 
crystals of free Prolyl Oligopeptidase. Large crystals of the 
protein with 2 were formed after the drops were seeded and 
left to equilibrate with the reservoir solution at +19˚C over 
a week. Crystals were picked up from the crystallization 
drop using a nylon loop, transferred directly into liquid 
nitrogen and stored until needed for data collection. The 
crystals diffracted well and a data set was collected to a 
resolution of 1.35Å with an oscillation range of 0.5º per 
frame on the beamline IO4 at DIAMOND synchrotron, 
Oxfordshire, using an ADSC CCD detector. The X-ray 
crystal diffraction pattern of Prolyl Oligopeptidase with 
bound inhibitor 2 is shown in the Supporting Information.  
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